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Background/aim: Measles is one of the important vaccine-preventable diseases with many complications in childhood. This study
presents cross-sectional seroepidemiological data, beginning from neonatal cord blood in infants to children under 6 years of age, about
waning of measles antibody and tries to suggest the proper time for measles immunization.
Materials and methods: A total of 564 blood samples consisting of neonatal cord blood and samples taken from infants and children at
ages of 6, 9, 24–48, and 49–72 months were analyzed for measles seropositivity in a period of 6 months.
Results: Measles seropositivity rate was 72.5% in 109 cord blood samples, 2.6% in 117 infants of 6 months of age, and 3.6% in 111 infants
of 9 months of age. Seropositivity was determined in 118 children at 24–48 months and in 109 children at 49–72 months and was 80.5%
and 66%, respectively (P = 0.001). These children were vaccinated in the 12th month.
Conclusion: Though measles immunization coverage is 97% in Turkey, population immunity is somewhat lower than expected.
Increases of measles cases in Europe and the refugee problem in the country could easily lead to outbreaks. Implementing the first dose
of the immunization at 9 months may be an option.
Key words: Childhood immunization, measles, measles elimination, measles epidemiology, measles immunization

1. Introduction
Measles is an important cause of morbidity and mortality
in children. Newborns are protected for some time by a
specific antibody transferred from their naturally infected
or previously vaccinated mothers, but as the antibody starts
to decrease after birth these infants become vulnerable
to measles [1–3]. However, regional elimination or
global eradication of measles is possible through proper
vaccination strategies and surveillance of the disease.
The World Health Organization has declared measles
as the third goal among eradicable infectious diseases
[4]. To achieve the highest antibody response in measles
immunization in infants, antibody decrease dynamics
should be well known. The goal of immunological response
and the disease risk should be balanced and measles
vaccination strategies should be developed accordingly,

as inhibiting the viral circulation becomes impossible
when the number of vulnerable individuals increases in a
community. Pertaining to our geography, with the ongoing
war very close to Turkey’s borders and mass movement of
unvaccinated refugees, especially from Syria, there is a
much bigger risk of epidemics with vaccine-preventable
diseases. Lately increasing measles cases in Europe and
vaccine refusals in the country are also adding serious
risks.
Seroepidemiological studies help to determine the
amount and duration of natural or vaccine-induced
antibodies and their preventive effects on diseases; thus,
they support surveillance and vaccine coverage studies for
the goals of control and elimination of vaccine-preventable
diseases. These studies are indispensable for establishing
disease seroprevalences in vulnerable age groups,

* Correspondence: seldapolat2003@hotmail.com

336

This work is licensed under a Creative Commons Attribution 4.0 International License.

KARAAYVAZ et al. / Turk J Med Sci
predicting the need for vaccine campaigns or extra doses
beyond national vaccine schedules and the effect of such
measures on population immunity, estimating the reasons
for epidemics, and setting vaccine coverage goals [5–8].
This study was planned to present cross-sectional
seroepidemiological data, beginning from neonatal cord
blood in infants to children under 6 years of age, about the
waning of measles antibody and to suggest the proper time
for measles immunization.
2. Materials and methods
This study was conducted in a period of 6 months with 564
healthy children in the Gazi University Medical School
Hospital in the capital city of Turkey. The study’s neonatal
arm comprised cord blood samples of newborns whose
mothers gave consent before delivery. A group of infants
and children who had been brought for well-child visits
and had no immunological problems or natural measles
infection history were recruited after obtaining parental
consent. All immunization documents were checked.
Recruited infants younger than 12 months of age were not
vaccinated for measles, while those older than 12 months
were vaccinated one time. Cord blood samples were
collected in the delivery room and the rest in the wellchild clinic after obtaining a detailed health history and
physical examination of the child.
After collecting blood samples of 5 mL, centrifugation
was completed immediately and serum samples of 3
mL were stored in a freezer at –70 °C in the hospital’s
microbiology laboratory. After terminating the study, all
samples were transferred to the Ministry of Health’s Public
Health General Directorate Microbiology Reference
Laboratory and National Virology Laboratory for testing.
Before testing, all samples were dissolved and processed
at room temperature. The analysis was performed with an
Enzygnost Anti-Measles Virus/IgG kit (Siemens, Marburg,
Germany) according to the manufacturer’s protocol. A
value of ΔA OD of <0.100 was accepted as anti-measles
IgG-negative while ΔA OD of >0.200 was anti-measles
IgG-positive and values between 0.100 and 0.200 were
anti-measles IgG-intermediate.
The study protocol was approved by the local
institutional ethics committee.
2.1. Statistical analysis
IBM SPSS version 21.0 (IBM Co., Armonk, NY, USA) was
used. For the categorical data, descriptive analysis was
performed and presented as number and percent values.
For comparisons chi-square and Fisher’s exact test were
used and P < 0.05 was accepted as significant. As the
anti-measles intermediate IgG values were very close to
the negativity limits, they were consequently accepted as
negative.

3. Results
A total of 564 infants and children were evaluated; age and
sex distributions for the entire group are shown in Table 1.
There were no statistically significant differences according
to the sex or age distributions (P > 0.05). Comparison of
measles seropositivity rate among sexes and age groups is
shown in Table 2.
Measles seropositivity rate was 72.5% in cord blood
samples (n = 109), 2.6% in infants who were 6 months
of age (n = 117), and 3.6% in infants who were 9 months
of age (n = 111). In 118 children of 24–48 months and in
109 children of 49–72 months of age, who were vaccinated
only once at 12 months, the seropositivity rate was 80.5%
and 66%, respectively (Figure).
When all the age groups were compared with each
other, statistically different seropositivity levels (P = 0.001)
were determined due to high levels of measles antibody
in newborns and in the 24–48 months of age category.
Similarly, the same significant difference was observed in
the comparison of all age groups within the same sexes (P
< 0.05).
4. Discussion
This study showed a low measles antibody positivity rate
of 72.5% in 109 newborn cord blood samples tested.
Table 1. Age and sex distribution of the study group.
N

Female (n) (%)

Male (n) (%)

Cord blood

109

61(56)

48 (44)

6 months

117

46 (39.3)

71(60.7)

9 months

111

61 (55)

50 (45)

24–48 months

118

50 (42.4)

68 (57.6)

49–72 months

109

60 (55)

49 (45)

Total

564

278 (49.3)

286 (50.7)

Table 2. Comparison of measles antibody seropositivity levels of
sexes among different age groups.
Age

Females
(n) (%)

Males
(n) (%)

P

Cord blood

46 (75.4)

33 (68.8)

0.519

6 months

0 (0)

3 (4.2)

0.278

9 months

2 (3.3)

2 (4)

1.00

24–48 months

39 (78)

56 (82.4)

0.640

49–72 months

39 (65)

33 (67.3)

0.841

Total

146 (52.5)

127 (45.7)

>0.05

P < 0.05 is significant.
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Figure. Measles antibody levels of the study group among ages.
*P = 0.001.

This finding is very low, particularly for a country with
low endemicity. It is well known that newborns already
having maternal measles antibody could also experience
severe disease when faced with a heavy measles load as
much as nonimmune neonates [9]. In a recent study,
measles antibody levels of neonates were compared among
countries and reported as 90% for Spain, 83% for the
Netherlands, 91% for Switzerland, and 80% for England
[10,11]. The mothers in the current study were expected to
have been vaccinated once during childhood, as a second
dose of measles immunization was only implemented
after 1998 in Turkey. One dose of measles vaccination is
not enough for maintaining the personal or population
immunity and sufficient antibody transfer to newborns
[12].
As Turkey has been fighting measles aggressively since
2000, the incidence of measles dropped from 12/100,000
to 0.7/100,000 in 2014 and so contacting the measles virus
and reboosting of the previous immunity decreased in
the community. Results of a study indicated that not only
newborns but also their mothers were vulnerable to the
disease as the initial concentration of maternal antibodies
in a newborn is strongly correlated with the mother [1].
Measles mortality rate is 1%–5% in infants between
6 and 11 months of age, with a higher mortality risk
particularly between 6 and 8 months [5,9]. In theory,
measles antibody transferred via the placenta to the
newborn has the potential to protect the infant during
the first 6–9 months [5,9]. It is postulated that antibody
transferred from vaccinated mothers remains for 3.5
months, whereas it is 2 months longer if the mother is
naturally immune. At the end of 6 months, all become
vulnerable [1,13,14].
Measles antibody seropositivity was found 2.6% in the
6-months group. The result was low and compatible with
the literature. In a study from Belgium, it was stated that
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in the infants of mothers who had been naturally infected
or vaccinated once during childhood, measles antibody
seropositivity was found to be 5% and 1% at 6 months of
age, respectively [13]. Lu et al. determined that maternally
transferred antibody starts to decrease at the third month
and mostly becomes negative at the seventh month with
a marked decrease in middle or low socioeconomic levels
[15].
In order to maintain measles control during this highly
vulnerable period, there is a need to achieve and sustain a
high population immunity, as measles vaccination in small
infants would not work due to immune immaturity and
maternally derived antibody [2].
In this study, measles antibody seropositivity was
3.6% in the 9-months group. However, a regional study
conducted in 2003 for the same age group of unvaccinated
infants in eastern Turkey showed a 50% measles antibody
seropositivity [16]. That remarkable difference probably
arose from the regional and temporal differences among
studies.
The measles antibody seropositivity in 118 children
of 24–48 months old was 80.5% and it was 66.1% in 109
children of 49–72 months old. The decrease in antibody
levels was more than expected. Approximately 5% of
measles antibody loss is expected 10–15 years after measles
vaccination [17].
Similarly, in a regional study conducted in Latin
America, after determining very low measles seropositivity
in vaccinated infants of 12–23 months old, protection and
transfer of vaccines and immunization practices were
revised [18].
Measles immunization programs aim to reach and
maintain ≥95% population immunity so as to protect
vulnerable groups and decrease the incidence of disease
[5,19]. In every community, for all age groups there
can be a sensitive pool even when measles seems to be
under control [12]. These vulnerable groups exist due to
many factors such as vaccination age, transplacentally
transferred antibody, effectiveness of vaccine, antibody
losses, and quality and regularity of health services, and
all have an effect on population immunity balance [20,21].
In Turkey, the first dose of measles immunization
is implemented at 12 months and the second dose is
in primary school, in the first grade. Actual measles
immunization coverage is declared to be 97% for 2 doses
[22], but unprotected individuals seem to be much more
than expected. Newborns and their mothers, infants under
12 months of age, and preschool children seem to be at
risk. In the first half of 2018, measles cases indicated a
10-fold increase in Turkey, rising from 9 cases to 85. The
predicted number was 200 cases by the end of the year.
Mass movement of the 3 million Syrian refugees to
the country also poses a risk as 1/3 of this population are
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children and only 200,000 are harbored in regular camps
with access to regular public health services and the rest
of the immigrant population resides widely scattered
in certain cities (http://multeciler.org.tr/turkiyedekisuriyeli-sayisi/). Moreover, childhood vaccine refusals are
increasing quickly in our community, parallel to the world,
and reached 24,000 cases in the last year.
The World Health Organization’s Regional Office for
Europe calls on all countries to immediately implement
broad, context-appropriate interventions to stop the
further spread of measles and outbreaks as over 41,000
children and adults were infected in the region in the first

half of 2018 with 37 deaths (http://www.euro.who.int/en/
home).
In conclusion, although measles immunization
coverage is 97% in Turkey, population immunity is
somewhat lower than expected. Increase of measles cases
in Europe and vaccine refusals in the country together
with the refugee problem could easily lead to outbreaks.
Implementing the first dose of immunization at 9 months
can be an option but more data are needed to decide on
the most appropriate immunization schedule for measles
in Turkey.
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